Costs of hyposensitization;Was kostet die hyposensibilisierung?

Allergo Journal

Volumn 16, Issue 8, 2007, Pages 586-590

  Mösges, Ralph ^a   Köberlein, Juliane ^a   Schog, Stephanie ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Allergic diseases; Health economic evaluation; Specific immunotherapy

Indexed keywords

ALLERGIC DISEASE; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; IMMUNOTHERAPY; PALLIATIVE THERAPY; REVIEW; SPECIFIC IMMUNOTHERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

EID: 38949100066     PISSN: 09418849     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03361702     Document Type: Review

References (14)

1. Bachert C, Vestenbaek U, Christensen J, Griffiths UK, Poulsen PB. Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. Clin Exp Allergy 2007; 37: 772-9
2. Blaiss MS. Important aspects in management of allergic rhinitis: compliance, cost, and quality of life. Allergy Asthma Proc 2003; 24: 231-8
3. Bousquet J, Lockey R, Malling H-J, and the Member Panel WHO. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-62
4. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham SR. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; 24: CD001936
5. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R. Utlization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999; 82: 339-47
6. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 802-9
7. Greiner W, Schulenberg J-M Graf v. d., Gillissen A. Kosten und Nutzen der Hyposensibilisierung bei allergischem Asthma und Rhinitis. Gesundh Ökon Qual Manag 2002; 7: 179-86
8. Günther J, Zawinell A. Was tun bei Heuschnupfen? Arzneimittelanalysen. In: AOK Wldo, Hrsg. Arzneimittelanalysen. Bonn: Wldo, 2006
9. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-8
10. Petersen KD, Gyrd-Hansen D, Dahl R. Health-economic analyses of subcutaneous specific immunotherapy for grass pollen and mite allergy. Allergol Immunopathol (Madr) 2005; 33: 296-302
11. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17: 37-52
12. Sieber J, Ott H, Baron J, Merk H. Wirksamkeit und Sicherheit der saisonalen SLIT bei allergischer Rhinitis gegen Gräserpollen - Ergebnisse der dreijährigen Behandlungsphase der ECRIT-Studie. Allergo J 2007; 16: 591 (Abstract)
13. Statistisches Bundesamt. Spezialbericht Allergie in Deutschland. Wiesbaden: Statistisches Bundesamt, 2000 (http://www.destatis.de, Zugriff: 23.04.2007)
14. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003; 2: CD002893